Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

@article{Baeten2013Antiinterleukin17AMA,
  title={Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.},
  author={D. Baeten and Xenofon Baraliakos and J{\"u}rgen Braun and Joachim Sieper and P T J Emery and D{\'e}sir{\'e}e Mfm van der Heijde and I Mcinnes and Jacob M van Laar and Robert L Landew{\'e} and Paul Wordsworth and Juergen Wollenhaupt and Herbert Kellner and Jacqueline E. Paramarta and Jiawei Wei and Arndt H Brachat and Stephan Bek and Didier Laurent and Yali Li and Ying A Wang and Arthur P Bertolino and Sandro Gsteiger and Andrew M Wright and Wolfgang Hueber},
  journal={Lancet},
  year={2013},
  volume={382 9906},
  pages={1705-13}
}
BACKGROUND Ankylosing spondylitis is a chronic immune-mediated inflammatory disease characterised by spinal inflammation, progressive spinal rigidity, and peripheral arthritis. Interleukin 17 (IL-17) is thought to be a key inflammatory cytokine in the development of ankylosing spondylitis, the prototypical form of spondyloarthritis. We assessed the efficacy and safety of the anti-IL-17A monoclonal antibody secukinumab in treating patients with active ankylosing spondylitis. METHODS We did a… CONTINUE READING